News for Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the 11 Best Long Term Low Risk Stocks to Invest in. Following the update on its ongoing clinical study, analysts are maintaining a Buy rating while raising the price target. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric disorders. Operating from its headquarters in California, […]

Neurocrine Biosciences (NBIX) received a noteworthy update from Morgan Stanley, as analyst Jeffrey Hung has made adjustments to the stock's price target. Despit

Truist Securities has initiated coverage on Neurocrine Biosciences (NBIX), announcing a "Buy" rating for the company. The coverage initiation was spearheaded by

An analyst from Truist, Danielle Brill, has started coverage on Neurocrine (NBIX) with a Buy rating, setting a price target of $163. Despite facing some challen

- New program combines IV-delivered TRACERâ„¢ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the p

PR NewswireSAN FRANCISCO, July 15, 2025 Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adren

Summary On July 14, 2025, Neurocrine Biosciences Inc (NBIX) announced new data from their Phase 3 CAHtalystâ„¢ studies, presented at the Endocrine Society's Ann

PR NewswireSAN DIEGO, July 14, 2025 Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achie

Neurocrine Biosciences' new drug, Crenessity, shows promise in a critical trial for congenital adrenal hyperplasia. Wall Street analysts see a potential

Neurocrine Biosciences (NBIX) has released new findings from their CAHtalyst Adult study involving the drug Crenessity. The study highlights that patients achie

Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the 11 best debt-free stocks to invest in right now. Following a recent investor meeting with Neurocrine Biosciences’ senior leadership, Guggenheim analyst Yatin Suneja reaffirmed a Buy rating on the stock on June 4, keeping his price target steady at $165. The discussion covered several key areas of interest […]

On July 10, 2025, Goldman Sachs initiated coverage on Neurocrine Biosciences (NBIX) with a "Buy" rating. The announcement was made by analyst Corinne Johnson, w

Goldman Sachs has begun coverage of Neurocrine (NBIX) with a Buy rating, setting a price target of $182, which suggests a potential increase of 36%. The investm

Summary Neurocrine Biosciences Inc (NBIX), a leading neuroscience-focused biopharmaceutical company, has announced that it will hold a conference call and webca

PR NewswireSAN DIEGO, July 9, 2025 Conference Call and Webcast Scheduled for Wednesday, July 30SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Bioscienc

Neurocrine Biosciences (NBIX) unveiled new patient-reported post-hoc data from the KINECT-HD study, which underscores notable reductions in both cognitive and m

Neurocrine Biosciences (NBIX) has revealed new insights from a Phase 4 study, highlighting significant improvements in health-related quality of life and functi

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. ( VYGR), a biotechnology company dedicated to leveraging genetics to treat neur

Voyager Therapeutics (VYGR) will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. The on-demand webcast will be available